Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuterol and Immune Cell Composition
NCT03889379Phase 1Withdrawn
- Sponsor
- University of Arizona
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of salbutamol in neuroblastoma, sponsored by University of Arizona. Primary endpoints: Quantification of NK Cells (CD3-/CD56+) at 1 year, Quantification of Gamma Delta T Cells (CD4-CD8-) at 1 year and 1 more. Planned start Jan 2019; status: withdrawn.
02
Drugs
salbutamol
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03889379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889379.